Dr Mark Tuthill

Dr Tuthill qualified in medicine from University College London in 2002 and became a member of the Royal College of Physicians (UK) in 2005. He undertook specialist training in medical oncology at leading London hospitals, including:

• The Royal Marsden
• Hammersmith Hospital
• Charing Cross Hospital
• Chelsea and Westminster Hospital

In 2009, he gained a postgraduate diploma in oncology from the Institute of Cancer Research, and in 2014 completed a PhD in tumour immunology at the MRC Clinical Sciences Centre and Imperial College London. He was appointed consultant medical oncologist at Oxford University Hospitals NHS Foundation Trust in 2015, where he continues to treat NHS patients alongside his private practice.

Contact details
Private secretary: Debbie Stephenson
Email: oncpp.docs@gmail.com
Mobile: 07795663703

Dr Tuthill welcomes patients for cancer treatment before or after surgery, for recurrence of cancer, or for a second opinion.

Patients can self-refer and do not need a GP or hospital specialist referral to see Dr Tuthill.

Dr Tuthill uses chemotherapy both to prevent cancer returning after surgery (for example in breast and bladder cancer) and to treat recurrence. His team also uses molecular tests such as Oncotype DX to identify which patients will benefit from chemotherapy in early breast cancer.

He also offers advanced antibody-drug conjugates, which combine cancer-targeting antibodies with chemotherapy payloads. These allow precision treatment with reduced side effects. Examples include Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan) for advanced breast cancer.

Immunotherapy has transformed outcomes for many cancers. Dr Tuthill routinely uses immunotherapy for early and advanced triple-negative breast cancer, kidney cancer, and bladder cancer. Treatments include Keytruda (pembrolizumab), Opdivo (nivolumab), and others, often in combination with chemotherapy to enhance results.

Targeted therapies are increasingly important in modern oncology. Dr Tuthill uses them across several cancers, including:

• Prostate and breast cancer (e.g., Olaparib for DNA repair mutations)
• Bladder cancer (Erdafitinib)
• Kidney cancer (tyrosine kinase inhibitors)
• Breast cancer (CDK4/6 inhibitors such as Ribociclib and Abemaciclib for recurrence prevention and advanced disease)

He also uses advanced molecular profiling tests such as FoundationOne, to personalise treatment choices.

Hormone-based treatments remain key for breast and prostate cancers. Dr Tuthill prescribes therapies such as Relugolix (Orgovyx), abiraterone, enzalutamide (Xtandi), and darolutamide (Nubeqa), with supportive strategies to minimise side effects, including menopausal symptoms in men and women.